Evidence map›Paper›PMID 27543804›Full record

ReviewBiochimica et biophysica acta2016

Mechanisms of transcription factor acetylation and consequences in hearts.

Devi Thiagarajan, Srinivasan Vedantham, Radha Ananthakrishnan, Ann Marie Schmidt, Ravichandran Ramasamy

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. NNature communications · 2023
    Article
  3. Review
  4. Deacetylation of Transcription Factors in Carcinogenesis.International journal of molecular sciences · 2021
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Histone deacetylase function in CD4Nature reviews. Immunology · 2018
    Review
  12. Review
  13. Acetylome ofFrontiers in molecular biosciences · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Devi ThiagarajanDiabetes Research Program, Division of Endocrinology, Department of Medicine, NYU Langone Medical Center, NY, New York 10016, United States.
Srinivasan VedanthamDepartment of Biotechnology, SASTRA University, Thanjavur, India.
Radha AnanthakrishnanDiabetes Research Program, Division of Endocrinology, Department of Medicine, NYU Langone Medical Center, NY, New York 10016, United States.
Ann Marie SchmidtDiabetes Research Program, Division of Endocrinology, Department of Medicine, NYU Langone Medical Center, NY, New York 10016, United States.
Ravichandran RamasamyDiabetes Research Program, Division of Endocrinology, Department of Medicine, NYU Langone Medical Center, NY, New York 10016, United States. Electronic address: ramasr02@nyumc.org.
NYU Langone Health · USSASTRA University · IN

Funding

RESEARCH TRAININGP30DK026687 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI Anthony W Ferrante, DYMPNA GALLAGHER · 1986 to 2026
$33.0M
Translational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI STREAMSON C CHUA · 2015 to 2026
$27.7M
VASCULAR AND MONOCYTE DYSFUNCTION IN WOUND REPAIRP01HL060901 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAMASAMY, RAVICHANDRAN, SCHMIDT, ANN MARIE · 1999 to 2017
$20.2M
TRANSGENIC MOUSE AND ANIMAL MANAGEMENTP01AG026467 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHMIDT, ANN MARIE · 2008 to 2014
$9.2M
RAGE, Diabetes and Myocardial InfarctionR01HL102022 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAMASAMY, RAVICHANDRAN · 2010 to 2014
$2.2M
ALDOSE REDUCTASE AND CARDIAC ISCHEMIC INJURYR01HL061783 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RAMASAMY, RAVICHANDRAN · 1999 to 2006
$1.9M
NHLBI NIH HHS P01 HL060901NHLBI NIH HHS R01 HL061783NHLBI NIH HHS R01 HL102022NIA NIH HHS P01 AG026467NIDDK NIH HHS P30 DK020541NIDDK NIH HHS P30 DK026687
6 · The paper itself

Abstract

Acetylation of proteins as a post-translational modification is gaining rapid acceptance as a cellular control mechanism on par with other protein modification mechanisms such as phosphorylation and ubiquitination. Through genetic manipulations and evolving proteomic technologies, identification and consequences of transcription factor acetylation is beginning to emerge. In this review, we summarize the field and discuss newly unfolding mechanisms and consequences of transcription factor acetylation in normal and stressed hearts. This article is part of a Special Issue entitled: The role of post-translational protein modifications on heart and vascular metabolism edited by Jason R.B. Dyck & Jan F.C. Glatz.

Indexed as

Protein Processing, Post-TranslationalAcetylationAnimalsCardiovascular DiseasesHumansMyocardiumTranscription FactorsTranscription FactorsAcetylationCardiovascular diseasesHeartHistone acetyl transferasesHistone deacetylasesTranscription factors

Identifiers

PMID27543804
PMCPMC5159280
OpenAlexW2517891003

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.